Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Immunovant (IMVT) EBT (2018 - 2026)

Immunovant filings provide 8 years of EBT readings, the most recent being -$109.1 million for Q4 2025.

  • Quarterly EBT rose 1.7% to -$109.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$460.6 million through Dec 2025, down 20.51% year-over-year, with the annual reading at -$412.9 million for FY2025, 59.58% down from the prior year.
  • EBT hit -$109.1 million in Q4 2025 for Immunovant, up from -$125.9 million in the prior quarter.
  • Across five years, EBT topped out at -$28.2 million in Q1 2021 and bottomed at -$125.9 million in Q3 2025.
  • Average EBT over 5 years is -$71.1 million, with a median of -$61.6 million recorded in 2022.
  • The largest annual shift saw EBT rose 18.0% in 2023 before it tumbled 115.37% in 2024.
  • Immunovant's EBT stood at -$41.4 million in 2021, then plummeted by 51.84% to -$62.8 million in 2022, then grew by 18.0% to -$51.5 million in 2023, then tumbled by 115.37% to -$111.0 million in 2024, then grew by 1.7% to -$109.1 million in 2025.
  • Per Business Quant, the three most recent readings for IMVT's EBT are -$109.1 million (Q4 2025), -$125.9 million (Q3 2025), and -$119.7 million (Q2 2025).